In all phases of pharmaceutical development and manufacturing activities and throughout the entire life cycle of our products, the primary objective is to protect the health and safety of our consumers. This commitment has been published in the "QUALITY POLICY" statement: "Leadership at the highest level ensures that an effective pharmaceutical quality system is in place, adequately resourced and ensures that roles, responsibilities and authorities are defined, communicated and implemented throughout the organisation. At the same time, Management ensures the support and commitment of staff to the pharmaceutical quality system at all levels and manufacturing sites in the organisation."

In our development projects, special emphasis is placed on providing state-of-the-art equipment and methods as well as employee expertise. The range of technological tools and equipment is constantly updated, as we consider it important to keep up with technological advances.

Employees participate in training programmes, presentations, courses and professional conferences, through which we aim to increase the level of professional competence of employees.

The company's pharmaceutical quality system encompasses all activities that can directly or indirectly influence product quality. Quality risk management is also implemented as a systematic process for assessing, controlling, communicating and re-examining risks to the quality of the medicine. Quality risk assessment is based on scientific knowledge and experience of the process and ultimately leads to patient protection. The level of effort, regulatory nature and documentation of the quality risk management process is commensurate with the level of risk.

Our production activities and our quality system are regularly inspected by both our contractual partners and the authorities. For years, these audits have been completed without critical observations.